MARKET

EDIT

EDIT

Editas Medicine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

58.68
+0.48
+0.82%
After Hours: 58.50 -0.18 -0.31% 18:20 09/21 EDT
OPEN
58.93
PREV CLOSE
58.20
HIGH
60.49
LOW
57.92
VOLUME
812.98K
TURNOVER
--
52 WEEK HIGH
99.95
52 WEEK LOW
27.01
MARKET CAP
4.01B
P/E (TTM)
-22.9928
1D
5D
1M
3M
1Y
5Y
'Fast Money Halftime Report' Picks For September 13
On CNBC's "Fast Money Halftime Report," Shannon Saccocia said Stryker Corporation (NYSE: SYK) has had a really nice run since last year.
Benzinga · 09/13 23:02
Final Trades: Stryker, Editas Medicine, Oracle & more
The "Halftime Report" traders give their top picks to watch for the second half.
CNBC.com · 09/13 17:56
Aadi Bioscience Appoints Emma Reeve to its Board of Directors
LOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announce...
GlobeNewswire · 09/13 12:00
Oppenheimer Upgrades Editas Medicine to Outperform From Perform, Adjusts PT to $80 From $42
MT Newswires · 09/10 12:23
Oppenheimer Upgrades Editas Medicine to Outperform, Raises Price Target to $80
Oppenheimer analyst Jay Olson upgrades Editas Medicine (NASDAQ:EDIT) from Perform to Outperform and raises the price target from $42 to $80.
Benzinga · 09/10 09:00
BRIEF-Editas Medicine Names Emma Reeve To Board Of Directors
reuters.com · 09/08 13:27
Editas Medicine Names Emma Reeve to Board of Directors
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Emma Reeve to its Board of Directors.
GlobeNewswire · 09/08 13:00
BRIEF-Editas Medicine Trial Data Of Edit-101 For Lca10 To Be Presented At The International Symposium On Retinal Degeneration
reuters.com · 09/07 20:41
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EDIT. Analyze the recent business situations of Editas Medicine through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EDIT stock price target is 53.92 with a high estimate of 81.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 418
Institutional Holdings: 58.41M
% Owned: 85.57%
Shares Outstanding: 68.26M
TypeInstitutionsShares
Increased
108
4.43M
New
47
385.57K
Decreased
81
4.91M
Sold Out
42
793.75K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/President/Chief Executive Officer/Director
James Mullen
Chief Financial Officer
Michelle Robertson
Executive Vice President/Chief Scientific Officer
Mark Shearman
Executive Vice President
Bruce Eaton
Executive Vice President
Lisa Michaels
Senior Vice President
Li Chi
Lead Director/Independent Director
Jessica Hopfield
Independent Director
Meeta Chatterjee
Independent Director
Andrew Hirsch
Independent Director
Emma Reeve
Independent Director
David Scadden
Independent Director
Akshay Vaishnaw
No Data
About EDIT
Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Webull offers kinds of Editas Medicine Inc stock information, including NASDAQ:EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.